Increased BCAT1 expression has been described in breast,47 ovarian,9 and liver cancer,8 and in AML5 and CML.15 However, its role in disease progression varies between different cancer types.14 BCAT1 is upregulated in a large proportion of IDH wild-type glioblastoma3,7,48 and has been identified as one of 4 independent prognostic markers of the disease,49,50 although the TCGA dataset shows that there is a wide variation in the levels of expression. The gene discussed is IDH2; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.